Literature DB >> 20126497

Hydroxypropyl cellulose ophthalmic inserts (lacrisert) reduce the signs and symptoms of dry eye syndrome and improve patient quality of life.

Marguerite McDonald1, Gerard D'Aversa, Henry D Perry, John R Wittpenn, Eric D Donnenfeld, Donald S Nelinson.   

Abstract

PURPOSE: A multicenter, 2-visit, open-label, 4-week study was conducted to determine the acceptability of hydroxypropyl cellulose ophthalmic inserts in adult patients with a history of dry eye syndrome (DES).
METHODS: At visit 1, patients (N = 520) were evaluated, screened by slit-lamp biomicroscopy, and completed the Ocular Surface Disease Index (OSDI), a validated measure of quality of life. Patients were trained in the proper placement and use of hydroxypropyl cellulose ophthalmic inserts and were contacted by telephone on day 3 of the study. At week 4, patients were given a clinical evaluation and completed a second questionnaire. Answers determined changes in symptoms and quality of life. Adverse events were monitored throughout the study.
RESULTS: Four hundred eighteen patients completed the study and reported significant improvements in discomfort, burning, dryness, grittiness, stinging, and light sensitivity (P = .05) after 4 weeks use of hydroxypropyl cellulose ophthalmic inserts. Significant improvements in clinical signs (keratitis, conjunctival staining, and tear volume) were reported. Contact lens wearers reported significant improvements similar to nonwearers, with a strong trend toward improvement in light sensitivity. Mean OSDI total scores, measuring quality of life, significantly improved by 21.3% (from 41.8 +/- 22.38 to 32.9 +/- 21.97, P < or = .0215). The most commonly reported adverse event leading to discontinuation was blurred vision, observed in 8.7% of patients (n = 45). Compliance during the study was good; 41.5% of subjects were fully compliant. Of the 58.5% of subjects who missed doses, the majority (69.4%) missed only one to five.
CONCLUSIONS: Hydroxypropyl cellulose ophthalmic inserts significantly reduced symptoms and clinical signs of moderate to severe DES. They also significantly improved DES in patients wearing contact lenses. Patients experienced a statistically significant improvement in quality of life, as measured by the OSDI, of 21.3%.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20126497      PMCID: PMC2814588     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  4 in total

Review 1.  Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007).

Authors: 
Journal:  Ocul Surf       Date:  2007-04       Impact factor: 5.033

Review 2.  Advances in understanding and managing dry eye disease.

Authors:  Michael A Lemp
Journal:  Am J Ophthalmol       Date:  2008-07-02       Impact factor: 5.258

Review 3.  The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007).

Authors: 
Journal:  Ocul Surf       Date:  2007-04       Impact factor: 5.033

Review 4.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007).

Authors: 
Journal:  Ocul Surf       Date:  2007-04       Impact factor: 5.033

  4 in total
  3 in total

1.  Light-responsive biomaterials for ocular drug delivery.

Authors:  Hend A M Abdelmohsen; Nikki A Copeland; John G Hardy
Journal:  Drug Deliv Transl Res       Date:  2022-06-24       Impact factor: 4.617

2.  Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye.

Authors:  Theresa Nguyen; Robert Latkany
Journal:  Clin Ophthalmol       Date:  2011-05-11

Review 3.  Advanced drug delivery and targeting technologies for the ocular diseases.

Authors:  Jaleh Barar; Ayuob Aghanejad; Marziyeh Fathi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.